Endpoint Selection Could Help Determine The NASH Race
Executive Summary
Sponsors in the hotly pursued and yet untapped field of non-alcoholic steatohepatitis think that selection of different primary or co-primary endpoints could help differentiate their programs in the competitive space.
You may also be interested in...
Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets
Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.
Galectin Plans To Head Into NASH Pivotal Studies Without Biopsy-Evaluated Endpoint
Company is moving its galectin-3 inhibitor into Phase III in non-alcoholic steatohepatitis patients with cirrhosis – a very advanced disease setting – and also to validate endpoints that don’t require liver biopsy.
Intercept's Revised NASH Trial Improves Prospects
The pivotal REGENERATE study of Ocaliva now can succeed if either of two co-primary endpoints is achieved. Intercept also will use a new "objective" definition of NASH resolution in the study.